At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Post-Market Trading 11-22 18:33:12 EST
1.81
+0.04
+2.26%
盘后1.79
-0.02-1.15%
18:29 EST
High1.85
Low1.69
Vol820.36K
Open1.80
D1 Closing1.77
Amplitude9.04%
Mkt Cap49.80M
Tradable Cap48.45M
Total Shares27.52M
T/O1.46M
T/O Rate3.06%
Tradable Shares26.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.